ORIC Pharmaceuticals, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2014

Location

San Francisco CA US

Primary Industry

Biotechnology

About

Founded in 2014 and based in California, US, ORIC Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded by Richard Heyman, Charles Sawyers, and Scott Lowe. In January 2024, ORIC Pharmaceuticals, Inc. raised USD 125 million in PIPE funding from Viking Global Investors, New Enterprise Associates, and Commodore Capital. As of 2024, the company is led by its CEO, Jacob Chacko. ORIC Pharmaceuticals develops therapies to address cancer resistance. The firm’s pipeline project includes ORIC-114, an orally bioavailable inhibitor targeting EGFR and HER2 mutations, including those found in brain metastases; ORIC-944, a drug targeting a protein complex (PRC2) involved in several cancers, including prostate cancer; and ORIC-533, an inhibitor of CD73, an enzyme that suppresses the immune system's ability to attack cancer cells. The company plans to use the funds raised in January 2024 to support the advancement of its clinical-stage product candidates.

Current Investors

KKR, OrbiMed Advisors, Topspin Partners

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment

Website

www.oricpharma.com

Company Stage

Mature

Total Amount Raised

Subscriber access only

Financials

Fiscal Year Ended
Revenue (USD)
% Revenue Growth (YoY)
Operating Income (USD)
Operating Margin
EBITDA (USD)
% EBITDA Margin
NET Income (USD)
% Net Margin

31 Dec 2017

(22,000,000)

(21,200,000)

(22,000,000)

31 Dec 2018

(21,400,000)

(20,500,000)

(21,400,000)

31 Dec 2019

(26,900,000)

(25,900,000)

(26,900,000)

31 Dec 2020

31 Dec 2021

31 Dec 2022

Unlock the recent years of financials and more for ORIC Pharmaceuticals, Inc..

Request a demo to see more.

Deals

Deals Type
PIPE

Deal Status	Target (s)	Deal Date	Investor(s)	Seller(s)	Deal size (Mn)	Enterprise value (Mn)	Post-money valuation (Mn)	EBITDA multiple (x)	Revenue multiple (x)	Lead partner (s)
Completed	ORIC Pharmaceuticals, Inc.	22 Jan 2024

Displaying 1-1 of 1

Employee Data

Want to see the Employee Count?

Request a demo for full access to this profile.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.